颈淋巴结阳性鼻咽癌调强放疗采用基于淋巴结大体靶区几何-解剖外扩一步法勾画颈部淋巴结临床靶区的长期结局:双中心经验
本研究汇总两个中国学术中心807例颈淋巴结阳性鼻咽癌患者,均采用从淋巴结大体靶区几何-解剖外扩一步法勾画淋巴结临床靶区并接受调强放疗。5年区域控制率95.8%、总生存率86.2%;34例区域失败中13例位于CTVn2外,以VIII区(腮腺淋巴结)9例最多。与2018年国际指南相比,该策略显著减少淋巴结治疗体积和预防体积及周围危及器官剂量。
要点
- 807例颈淋巴结阳性鼻咽癌一步法CTVn勾画后5年区域控制率95.8%、总生存率86.2%。
- 34例区域失败中13例位于CTVn2外,VIII区9例、Ib区4例、IV区2例。
- 与2018年国际指南相比,淋巴结V70平均100.7 vs 27.5 cc、V45平均343.5 vs 261.2 cc,均P<.001。
核心结论
- 作者认为,从GTVn几何-解剖外扩一步法勾画CTVn在颈淋巴结阳性鼻咽癌中似乎是安全高效的方法,区域控制优秀且在部分患者中有潜在剂量学获益。
- 作者提醒,对已有「可疑」淋巴结的患者需谨慎保护腮腺,对rENE晚期或II区淋巴结巨大(>5 cm)者需谨慎保护Ib区。
研究设计与样本
- 本研究汇总两个中国学术中心接受同一种一步法CTVn勾画治疗的颈淋巴结阳性鼻咽癌患者,共807例(中心1 n=459,中心2 n=348)。
- GTVn处方剂量为70 Gy等效,省略CTVn1,CTVn2处方45至55 Gy等效,定义为GTVn+3 mm几何外扩(放射学结外侵犯阳性[rENE+]时为5 mm)加按颈部淋巴结分区解剖边界定义的预防性淋巴结区域。
- 分析区域控制率和总生存率;随机选取15例按2018年国际指南重新勾画CTVn,比较两种勾画方法的剂量/体积。
主要发现
- 5年区域控制率为95.8%,5年总生存率为86.2%。
- 34例发生区域失败,其中13/34(38%)位于CTVn2外:VIII区(腮腺淋巴结)9/13、Ib区4/13、IV区2/13。
- 9例VIII区失败中7例存在既往「可疑」淋巴结;4例Ib区失败均存在「可疑」淋巴结且伴rENE晚期或II区淋巴结巨大(>5 cm)。
- 与2018年国际指南相比,该策略显著减少接受治疗剂量(V70)的淋巴结体积(平均100.7 vs 27.5 cc;P<.001)和预防剂量(V45)的淋巴结体积(平均343.5 vs 261.2 cc;P<.001),并进一步降低周围危及器官剂量。
关键数值与推荐
- GTVn处方70 Gy等效,CTVn2处方45至55 Gy等效。
- CTVn2为GTVn+3 mm几何外扩(rENE+时为5 mm)加按颈部淋巴结分区解剖边界定义的预防性淋巴结区域,省略CTVn1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report long-term results of patients with cervical node-positive (CLN+) nasopharyngeal carcinoma (NPC) treated with intensity modulated radiation therapy with one-step nodal clinical target volume (CTVn) delineation by geometric-anatomic expansion from the nodal gross target volume (GTVn). METHODS AND MATERIALS: Patients with CLN+ NPC treated with the same one-step-CTVn delineation in two Chinese academic centers were pooled for this study. GTVn was prescribed to 70 Gy equivalent, CTVn1 was omitted, CTVn2 was prescribed to 45 to 55 Gy equivalent, and defined as GTVn + 3 mm geometric expansion (5 mm if radiological extranodal extension-positive [rENE+]) + elective nodal regions defined by anatomic boundary of cervical nodal levels. Regional control (RC) and overall survival (OS) were analyzed. Fifteen randomly selected cases were recontoured for CTVn according to the 2018 International Guidelines (2018-IG). Dose/volume was compared between the two clinical target volume delineation methods. RESULTS: A total of 807 patients were included (center 1, n = 459; center 2, n = 348). Five-year RC and OS were 95.8% and 86.2%, respectively. Thirty-four patients developed regional failure, and 13/34 (38%) were outside CTVn2: level VIII (parotid node) (9/13), Ib (4/13), and IV (2/13). Seven out of these 9 level VIII failures had pre-existing "equivocal" nodes. All 4 level 1b failures had "equivocal" nodes with very advanced rENE or large (>5 cm) nodal mass in level II. Compared with the 2018-IG, our strategy resulted in significant reduction in nodal volumes received therapeutic (V70) (mean, 100.7 vs. 27.5 cc; P < .001) and prophylactic (V45) (mean, 343.5 vs. 261.2 cc; P < .001) doses and further dose reduction in surrounding organs at risks. CONCLUSIONS: Our one-step-CTVn delineation by geometric-anatomic expansion from GTVn appears to be a safe and efficient approach in CLN+ NPC, with excellent RC and potential dosimetric benefits in selected patients. Caution is needed for parotid sparing in patients with pre-existing "equivocal" nodes or level Ib sparing in cases with advanced rENE or large (>5 cm) nodal mass in level II.
引用
- Guo Q, Huang J, Xiao N, et al. Long-Term Outcome in Cervical Lymph Node-Positive Nasopharyngeal Carcinoma Following Intensity Modulated Radiation Therapy With One-Step Cervical Nodal Clinical Target Volume Delineation by Geometric-Anatomic Expansion From Nodal Gross Target Volume: A Double-Center Experience. Int J Radiat Oncol Biol Phys. 2024. PMID: 39674327. doi:10.1016/j.ijrobp.2024.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。